Oncimmune Holdings plc (ONC.L)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Martin John Gouldstone | CEO & Director | 255k | -- | 1966 |
| Mr. Martin Hudson | Chief Financial Officer | -- | -- | -- |
| Dr. Petra Budde | Chief Scientific Officer | -- | -- | -- |
| Ms. Cléa Rosenfeld | Head of Investor Relations | -- | -- | -- |
Oncimmune Holdings plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 40
Description
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
Corporate Governance
Upcoming Events
May 19, 2025 at 10:59 AM UTC - May 23, 2025 at 12:00 PM UTC
Oncimmune Holdings plc Earnings Date
Recent Events
Recent Events Information Not Available